New drug combination after initial chemotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer (or a very similar type called TNBC-like), confirmed by a biopsy.
- Your cancer must be stage II or III at the time of diagnosis, and it must not have spread to other parts of your body.
- You must be at least 18 years old and able to understand and fill out quality-of-life questionnaires.
- You must have already received 9 to 12 weeks of a standard chemotherapy combination (carboplatin and paclitaxel, with or without pembrolizumab) and be within 2 weeks of your last dose.
- Your doctor must be able to provide a sample of your tumor tissue for a central pathology review.
- You need to be in reasonably good health, with adequate kidney, liver, and blood counts, and a normal heart rhythm (ECG).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.